Vasopressin Infusion Dosing in Vasodilatory and Septic Shock
For adult patients with vasodilatory or septic shock, initiate vasopressin at 0.01-0.03 units/minute as an adjunct to norepinephrine, with a maximum dose of 0.03-0.04 units/minute. 1, 2
Starting Dose and Administration
The FDA-approved dosing range is:
However, the most widely recommended and evidence-based dose is 0.03 units/minute or less 1, 2. The 2017 Surviving Sepsis Campaign guidelines specifically state that vasopressin at 0.03 units/minute can be added to norepinephrine to either raise MAP or decrease norepinephrine requirements 1. The 2025 ESICM guidelines reinforce adding vasopressin up to 0.03 U/min to norepinephrine 3.
Critical Dosing Principles
Do not use vasopressin as monotherapy. It should never be the single initial vasopressor for sepsis-induced hypotension 1. Norepinephrine remains the first-line agent, and vasopressin is added as adjunctive therapy 1, 3.
Do not titrate vasopressin like other vasopressors. Unlike norepinephrine, vasopressin is administered at a fixed low dose rather than being titrated to blood pressure targets 4, 5. The dose should remain between 0.01-0.03 units/minute 1.
Doses exceeding 0.04 units/minute should be reserved for salvage therapy only when other vasopressor agents have failed to achieve adequate MAP 1, 2.
Timing of Initiation
Recent evidence suggests earlier initiation may be beneficial. The 2026 target trial emulation found that initiating vasopressin within 0-3 hours after norepinephrine reached 0.25 μg/kg/min was associated with lower 28-day mortality (48.1% vs 53.0%) compared to initiation at 3-6 hours 6. Another 2026 multicenter study showed that starting vasopressin at norepinephrine doses ≥0.5 μg/kg/min was associated with higher mortality (aOR 2.15) compared to initiation at <0.25 μg/kg/min 7.
Practical recommendation: Consider adding vasopressin when norepinephrine requirements reach 0.25 μg/kg/min, rather than waiting for higher doses or refractory shock 6, 7, 8.
Preparation and Infusion
Dilute the 20 units/mL vial with normal saline or D5W to either 0.1 units/mL or 1 unit/mL 2. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration 2. Administer via continuous intravenous infusion through a central line when possible.
Pharmacodynamics
The pressor effect reaches peak within 15 minutes and fades within 20 minutes after stopping the infusion 2. Steady-state plasma concentrations are achieved after 30 minutes of continuous infusion 2. There is no evidence of tachyphylaxis or tolerance to vasopressin's pressor effect 2.
Key Adverse Effects to Monitor
- Cardiac dysfunction: Vasopressin tends to decrease heart rate and cardiac output 2. Use cautiously in patients with cardiac dysfunction 2.
- Ischemic complications: Monitor for coronary, mesenteric, skin, and digital ischemia 2, 5
- Hyponatremia: Due to V2 receptor-mediated antidiuretic effects 2
- Gastrointestinal hypoperfusion 4
Limiting the dose to 0.03 units/minute or less minimizes these adverse effects 5.
Clinical Benefits
Beyond blood pressure support, vasopressin at these doses:
- Reduces norepinephrine requirements 9, 5
- May improve renal function and reduce need for renal replacement therapy 9, 7
- May increase urine output 5
- Provides vasoconstriction through non-adrenergic mechanisms, supporting "decatecholaminization" strategies 10
The landmark VASST trial showed no overall mortality benefit compared to norepinephrine alone, but suggested benefit in less severe shock (norepinephrine 5-14 μg/min) 9, 11.